Psychedelics Stocks
The emerging mental health treatment paradigm.
11 Psychedelics Stocks companies
Psychedelic-assisted therapy is advancing through clinical trials and toward regulatory approval. MDMA for PTSD, psilocybin for depression, and other compounds are demonstrating efficacy that could transform mental health treatment.
The sector has experienced significant volatility as early hype gave way to the realities of drug development timelines and regulatory uncertainty. But clinical data continues to accumulate. FDA breakthrough therapy designations signal regulatory interest. And the mental health crisis creates urgency for new treatment modalities.
The New Money tracks psychedelics companies navigating the path to approval. Clinical trial results, regulatory milestones, intellectual property development, and the financing rounds sustaining research programs. The stigma is fading. The science is advancing.
Companies in Psychedelics Stocks
AbbVie is a global biopharmaceutical company focused on therapies in immunology, oncology, neuroscience, and other specialized areas.
AtaiBeckley develops and advances clinical-stage psychedelic-based and neuropharmacology therapies for mental health conditions, including treatment-resistant depression.
Bionomics develops novel ion channel modulators for treating serious central nervous system disorders like anxiety and PTSD.
Compass Pathways pioneers evidence-based mental health innovations, developing psilocybin therapies for treatment-resistant depression and other serious conditions.
Cybin is a biopharmaceutical leader developing innovative psychedelic-based therapeutics for mental health, including depression and anxiety disorders.
MIRA Pharmaceuticals develops novel oral ketamine and marijuana analogs to treat neurologic and neuropsychiatric disorders.
MindMed pioneers psychedelic-inspired therapies to address mental health disorders, aiming to transform treatment for anxiety, ADHD, and autism spectrum disorder.
Optimi Health Corp., a Canadian-based company, produces and supplies GMP-certified MDMA and psilocybin for mental health treatments, licensed by Health Canada.
Pasithea Therapeutics develops innovative treatments for central nervous system disorders, focusing on conditions like ALS, multiple sclerosis, and neurofibromatosis type 1.
PharmAla Biotech is a Canadian company specializing in the research, development, and manufacturing of clinical-grade MDMA and novel MDXX compounds.
Silo Pharma develops novel therapeutics for PTSD, chronic pain, and CNS diseases, merging traditional and psychedelic research to address unmet medical needs.
Recent Psychedelics Stocks articles
There’s A New Executive Order For Psychedelics In The USA
President Donald Trump signed a new executive order known as Accelerating Medical Treatments for Serious Mental Illness focused on using psychedelic medicines.
Compass Pathways Validates Psilocybin Derived Drug In Phase III Clinical Trial
Compass Pathways (NASDAQ: CMPS) has successfully achieved the primary endpoint for their COMP360 drug in their second Phase III trial for treating depression.
Christian Angermayer’s AtaiBeckley Is All In On Psychedelic Medicines In America
Psychedelic drug development company AtaiBeckley (NASDAQ: ATAI) has officially completed their redomiciliation into the United States of America.
AbbVie Is Spending A Billion Dollars To Buy A Psychedelic Drug
AbbVie (NYSE: ABBV) has struck a deal with psychedelic drug development company Gilgamesh Pharmaceuticals to acquire their novel serotonergic psychedelic drug.
Christian Angermayer Piles Into Psychedelic Drug Developer Stock
Christian Angermayer has publicly disclosed he has purchased $19M USD worth of common shares in atai Life Sciences (NASDAQ: ATAI).
Cybin Secures $500 Million Dollar Deal For Psychedelic Drug Development
Cybin (NYSE: CYBN) has entered into a new securities purchase agreement with High Trail Special Situations for up to $500M USD to fund their clinical trials.
The State of Texas Is Funding New Ibogaine Research
Texas Governor Greg Abbott has officially signed Senate Bill 2308 into law which will allow for $50 million in state funds to go towards researching ibogaine.
atai Life Sciences and Beckley Psytech Merge To Form Psychedelic Giant
atai Life Sciences (NASDAQ: ATAI) and Beckley Psytech have officially announced their intention to merge in a new all stock deal.
Washington Has A Powerful New Advocate For Psychedelics
The United States Department of Health and Human Services has officially appointed attorney Matt Zorn as Deputy General Counsel.
Cybin Is Preparing For Psychedelic Assisted Therapies In America
Cybin (NYSE: CYBN) has announced a new partnership with clinical technology company Osmind to accelerate commercial preparations for their novel psychedelic.
The Publicly Traded Psychedelic Drug Developer Buying Bitcoin
atai Life Sciences (NASDAQ: ATAI), one of the most advanced publicly listed psychedelic companies, has purchased $5M USD of Bitcoin to hold as an asset.
PharmAla Biotech Is Bringing MDMA To The Netherlands
PharmAla Biotech (CSE: MDMA) has struck a new deal with pharmaceutical wholesale company Duchefa Farma to distribute MDMA in The Netherlands.
